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Summary
Background: Combination drug therapy of brucellosis leads to recovery of symptoms, shortening
of symptomatic interval, and decrease in morbidity rate, but single drug therapy is associated
withmore relapse episodes and a higher rate of drug resistance. Different drug combinations have
been evaluated in the treatment of brucellosis. Considering the failure of treatment and
relatively high rate of relapse of the disease with the World Health Organization’s (WHO)
recommended therapeutic regimen, we evaluated a new regimen that we assumed would
increase the success of treatment and decrease the rate of relapse. In this study we compare
the standard regimen of the WHO, doxycycline—rifampin (DR), to triple therapy with doxycy-
cline—rifampin—amikacin (ADR).
Methods: Two hundred and twenty-eight consecutive patients with brucellosis, who attended
Hamedan Sina Hospital between 1999 and 2001, whether seen as outpatients or as inpatients,
were enrolled in the study. The participants were randomly allocated to the DR group (receiving
doxycycline 100 mg twice a day and rifampin 10 mg/kg body weight/day every morning, both
taken orally for eight weeks) or the ADR group (receiving doxycycline 100 mg twice a day and
rifampin 10mg/kg body weight/day every morning, both taken orally for eight weeks, plus
7.5 mg/kg amikacin intramuscularly twice a day for seven days). The patients were checked for
the relief of symptoms, drug side-effects, and relapse of disease during the treatment and follow-
up.
Results: Of the 228 patients enrolled, eight were withdrawn — four patients from the DR group
and four from the ADR group. Of the remaining 220 participants (110 in the ADR group and 110 in
the DR group), 107 weremale (48.6%) and 113 were female (51.4%). Mean age was 35.7  17 years* Corresponding author. Tel.: +98 918 1113037; fax: +98 811 8267043.
E-mail address: ahmaliver@yahoo.com (M. Ranjbar).
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in the ADR group and 37  18.4 years in the DR group ( p = 0.5). In the DR group, 97 (88.2%) and in
the ADR group, 106 (96.4%) of the patients had relief of symptoms (a significant difference by Chi-
square test ( p = 0.04)). After completion of treatment, and at the sixth month follow-up, nine
(9.3%) patients in the DR group and six (5.7%) in the ADR group experienced a relapse of the
disease, with no significant difference (p = 0.4). Mild side-effects were found in only 10 patients,
and none required discontinuation of the therapeutic regimen. Of these patients, four were from
DR group and six from ADR group; no significant difference was observed ( p = 0.7).
Conclusions: Given the fact that the ADR regimen had a higher efficacy and more rapid action in
terms of relief of symptoms compared to the DR regimen, and that no significant difference in
drug side-effects and disease relapse existed in the patients of either group, adding amikacin to
the DR standard treatment regimen seems beneficial.
# 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.Introduction
Brucellosis is an important zoonotic disease. Brucella bac-
teria can infect patients via a number of different routes
including skin wounds or scratches (in occupational contact),
conjunctiva, air-borne particles, and consumption of con-
taminated livestock products.1,2 Brucellosis has a wide range
of manifestations from an acute febrile illness to mild non-
specific complaints, and its duration varies from several days
to several years.
More than half a million new cases from 100 countries are
reported annually to the World Health Organization (WHO).
The majority of cases are living in developing countries.3 In
Iran, brucellosis is a prevalent disease; it is endemic in some
provinces including Khorasan, Gilan, Mazandaran, Chahar-
mahal and Bakhtiari, and Hamedan.4 In 2001 the incidence
of brucellosis in Iran was 25/100 000 population, and in 2004
the incidence had increased (38/100 000). In Hamedan
(west of Iran) the incidence of brucellosis in 2004 was
121/100 000.
Combination drug therapy of brucellosis leads to recovery
of symptoms, shortening of symptomatic interval, and a
decrease in morbidity rate, but single drug therapy is asso-
ciated with more relapse episodes and a higher rate of drug
resistance.5 In 1986 a doxycycline—rifampin (DR) regimen for
six weeks was recommended by theWHO as the standard drug
therapy for brucellosis.2 In experimental studies, different
drug therapy regimens have been compared, such as DR and
doxycycline—streptomycin (DS). In one study, the DR regimen
failed in 8% of cases compared with a 2% failure rate in DS
therapy. The relapse rates were 16% and 5.3% in DR and DS
groups, respectively.6
Given the fact that therapeutic drug regimens with ami-
noglycosides have higher therapeutic success rates, and the
fact that long-term use of these agents is associated with
significant nephrotoxicity, we decided to compare the drug
regimen recommended by the WHO (DR) with a therapeutic
regimen including doxycycline—rifampin and a short course
of an aminoglycoside (amikacin for one week) (ADR).
In research on brucellosis in Iran, Brucella melitensis has
been reported as the most common type of Brucella. Zowghi
and colleagues confirmed the high frequency of Brucella
melitensis by extraction from infected sheep and goats. In
this study 1014 samples from products of conception, includ-
ing aborted fetuses of infected sheep and goats, were cul-
tured at the Razi Institute, Tehran, Iran, between 1994 and1996. Brucella was identified in 488 samples including 377
Brucella melitensis (biotype 1), 26 Brucella melitensis (bio-
type 2), 83 Brucella melitensis (biotype 3), and two Brucella
abortus.7 Due to this high frequency of Brucella melitensis,
and to the high relapse rate of brucellosis that has been
evident in Iran since 1997, the National Committee of Bru-
cellosis of Iran proposed an eight-week therapy for brucel-
losis; on this basis we designed our eight-week study
treatment period. Our main focus was to investigate the
effect of agents that already have a proven profile of effec-
tiveness, in a new combination.Methods
We calculated the sample size based on a confidence interval
of 95% (a = 0.05) and a study power of 80% (b = 0.20). Our
literature review showed that the probability of complete
relief in patients receiving the DR regimen it is about 80% (P1)
while for patients receiving the ADR regimen is about 94%.
The probability of losing cases during the course of study was
estimated to be 10% ( f = 10%) based on the results of other
studies in the same setting. Based on these parameters the
sample size required for each group was calculated to be 114
cases. So the total number of cases required for the study
was 228.
In this study 228 consecutive patients with brucellosis who
attended the Hamedan Sina Hospital between 1999 and 2001,
whether seen as outpatients or as inpatients, were enrolled.
A diagnosis of brucellosis was defined as: (1) brucellosis
clinical features including fever, sweats, arthralgia, hepato-
megaly, splenomegaly, and/or signs of focal disease with a
1/160 standard tube agglutination titer of antibodies to
Brucella; or (2) a tissue sample or blood culture positive for
Brucella bacteria; or (3) a four-fold increase in Wright titer in
a two-week interval with compatible clinical findings.2
We did not use culture media (Castaneda) or rapid isola-
tion techniques (e.g., BACTEC) for every case. Of the 228
patients, blood from 85 cases was cultured. For all patients
who experienced a relapse or therapeutic failure, blood
samples were cultured. In the absence of bacteriologic con-
firmation, a presumptive diagnosis can be made on the basis
of high or rising titers of specific antibodies and characteristic
clinical findings (fever, sweats, arthralgias, hepatomegaly,
splenomegaly, and lymphadenopathy).2
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Figure 1 Percentage of patients with fever over the course of
the first four weeks of treatment with either doxycycline—
rifampin—amikacin (ADR) or doxycycline—rifampin (DR).In our study therapeutic failure was considered to have
occurred if symptoms or signs of the disease persisted at the
end of treatment, and relapse was defined by the reappear-
ance of symptoms or signs of the disease or new positive
blood cultures after therapy. A 2-mercaptoethanol (2-ME)
Wright’s test was carried out for all of the patients at the
beginning of the study and at the end of the second and sixth
months. Pregnant women, children under eight years of age,
and patients with endocarditis and neurobrucellosis were
excluded.
All the cases signed an informed consent document before
the commencement of therapy. The ethics committee of the
Hamedan University of Medical Sciences approved the study.
Using a table of random numbers, we assigned patients
to receive either DR or ADR combination therapy. Patients in
the DR group received doxycycline 100 mg twice a day plus
rifampin 10 mg/kg body weight/day every morning, both
taken orally for eight weeks. Patients in the ADR group
received doxycycline 100 mg twice a day and rifampin
10 mg/kg body weight/day every morning, both taken
orally for eight weeks, plus 7.5 mg/kg amikacin intramus-
cularly twice a day for seven days. Every patient was
checked on days 7, 14, and 28, and at the end of therapy
for drug side-effects. Compliance with treatment was
emphasized in interviews conducted during the treatment
period, and during the treatment phase this was checked at
each visit (days 7, 14, 28, and at the end of therapy) by
counting the pills remaining in drug containers. At these
visits the subjects were asked whether they had missed any
doses. For determination of aminoglycoside nephrotoxicity
the patients were assessed at the outset and on days 7, 14,
28, and the end of therapy. If initial creatinine was normal,
nephrotoxicity was either the elevation of creatinine to 1.5
or higher or an absolute increase of 0.4 mg/dL. Ototoxicity
was assessed by audiometric study at the beginning of
treatment and on day 14. Vestibular dysfunction was
emphasized in interviews conducted during the treatment
period.
At two months all the patients were checked for the
presence of signs and symptoms, and laboratory results were
studied. If recovery was achieved at this stage the treatment
regimen was discontinued, but if signs and symptoms per-
sisted the same therapeutic regimen was continued for a
further four weeks. At three months, if the patient had made
a full recovery, no further treatment was administered and a
six-month follow-up was pursued. If the signs and symptoms
persisted at the 12th week the patient was considered a case
of therapeutic failure.
All patient information was recorded and analyzed with
SPSS 10 software. A per protocol analysis was performed.
Results
Of the 228 patients enrolled in the study, eight were with-
drawn (four in the DR group and four in the ADR group): five
patients did not take the prescribed drugs correctly (three in
the DR group and two in the ADR group), and three patients
had a follow-up period of less than six months (one in the DR
group and two in the ADR group). Of the remaining 220
participants (110 in each group), 107 were male (48.6%)
and 113 were female (51.4%). In the ADR group 49% weremen and in the DR group 48.2% were men, which made the
two groups comparable in terms of sex distribution ( p = 0.9
for group difference). Of all participants, 110 (50%) lived in
urban areas and the rest in rural regions. Mean age was
35.7  17 years in the ADR group and 37  18.4 years in
the DR group ( p = 0.5).
From 85 positive blood cultures (40 in the DR group and 45
in the ADR group) only 16 patients had a blood culture
positive for Brucella melitensis (seven in the DR group and
nine in the ADR group). Sixty-nine cases had a negative blood
culture. Blood culture results were positive in one patient in
the relapse group and one patient in the failure group (both in
the DR group). Relief of symptoms was found in 97 (88.2%)
patients in the DR group and in 106 (96.4%) patients in the
ADR group. This was found to be a significant difference by
Chi-square test ( p = 0.04, 95% CI 0.008—0.15). In the ADR
group 85 (80.2%) were treated for eight weeks and the rest
were treated for 12 weeks while in the DR group 60 (61.9%)
were treated for eight weeks and 37 (38.1%) received treat-
ment for 12 weeks ( p = 0.006).
Particular care was given to record fever relief as accu-
rately as possible because fever had an important place in the
monitoring of patient treatment. At baseline 203 (92.3%) of
the patients had fever (103 in the ADR group and 100 in the DR
group). In the DR group, at the end of the secondweek 68 cases
(68%) were afebrile and at the end of the third week 95 cases
(95%) were afebrile. In five patients (5%) fever persisted until
the fourth week. In the ADR group, at the end of the second
week 95 cases (92.2%)were afebrile and at the end of the third
week 102 cases (99%) were afebrile; only one case was febrile
until the fourth week (Figure 1). This difference between the
two groups was significant (p = 0.0001, CI 0.15—0.35).
As shown in Table 1, after the completion of treatment, at
the six-month follow-up, nine (9.3%) patients in the DR group
and six (5.7%) in the ADR group experienced a relapse of the
disease, with no significant difference ( p = 0.4). At two and
six months the 2-ME titer was checked. Of all patients, 188
were 2-ME negative at six months. In the DR group, 43 (39.1%)
and 45 (40.9%) patients were 2-ME negative at the second and
sixth months, respectively. In the ADR group at two- and six-
months, 57 (51.8%) and 43 (39.1%) were 2-ME negative,
respectively, and the difference was significant ( p = 0.03,
CI 0.01—0.27).
Mild side-effects were found in only 10 patients. Of these,
four were from the DR group and six from the ADR group; no
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Table 1 Demographic and treatment outcome comparisons
between the two treatment groups
DR group ADR group p Value
n = 110 n = 110
Male sex 48.2% 49% 0.9
Percentage living
in urban areas
50% 50% 1
Mean age 
SD (years)
37  18.4 35.7  17 0.5
Symptom relief 88.2% 96.4% 0.04
Fever relief
at 2 weeks
68% 92.2% 0.0001
Drug side-effects 3.6% 5.5% 0.7
Relapse of disease 9.3% 5.7% 0.4
DR, doxycycline-rifampin; ADR, doxycycline-rifampin-amikacin.significant difference was observed ( p = 0.7). In both groups,
the treatment was usually well tolerated, although some
patients had mild and reversible adverse effects. In no case
were adverse effects severe enough to warrant discontinua-
tion of therapy. In the DR group two patients had mild gastric
complaints, one patient had vomiting, and one patient had
genital candidiasis. In the ADR group four patients had mild
gastric complaints and two patients had phototoxicity. At the
end of therapy there was no impairment of renal function or
ototoxicity in any patients.
Discussion
The two groups were similar in terms of age, sex, and where
they lived (urban/rural locations). This showed that the two
groups were similar enough to make a comparison between
the results possible.
The male to female ratio was nearly one in our study. In
industrial countries this ratio is 5/1 to 6/1, which is not
comparable with that of our study.8 Also in two other studies
performed by Hashemi9 and Haddadi8 in Hamedan and Teh-
ran, respectively, the prevalence of disease among women
was higher than that reported in reference books, which
might be the result of high non-pasteurized dairy consump-
tion by women, and of women working in animal husbandry
with men.
In this study we aimed to compare the efficacy of this
new treatment regimen and the regimen recommended by
the WHO. The rate of symptom relief in the ADR group was
significantly higher than that in the DR group. During
the first eight weeks of therapy, the ADR group had a
significantly better response to treatment compared to
the DR group. In other words, patients with the ADR
treatment regimen experienced a more rapid and better
recovery.
In a study by Haddadi8 the recovery rate with the DR
regimen was 88% and with a co-trimoxazole—rifampin—gen-
tamicin regimen was 90.5%, which was higher than that of the
standard regimen recommended by the WHO. In one study in
Spain in 1995, the failure rate with the DR regimen was 8%
and with a doxycycline—streptomycin regimen was 2%, which
was comparable to our findings (11.8% failure rate with DR).6
However a study in Saudi Arabia in 2001 reported a highresistance to rifampin and streptomycin during the previous
10 years, and as a result a 12-week treatment with this
regimen was recommended for all patients with brucello-
sis.10 In a cohort study in Spain in 1997, the efficacy and rate
of complications of a 45-day treatment with doxycycline—
gentamicin on human brucellosis was investigated. In none of
the patients did therapeutic failure occur. Only in one case
(5.9%) did the disease relapse after treatment.11
Relief of fever in patients under treatment is an appro-
priate marker for evaluating the rate of response to therapy.
In our study 92.3% of the patients had fever at baseline, which
is comparable to other reports (93—95%).2—4 The fever relief
in the ADR group was significantly higher than that in the DR
group at two weeks, and the persistence of fever at the
fourth week of treatment was significantly less in the ADR
group than that observed in the DR group. This suggests that
the new regimen is more efficient and acts faster on the relief
of symptoms. In a study by Hashemi,9 in the DR group fever
was relieved in 67.7% of patients at two weeks and in 96.6% of
patients at three weeks. The results are similar to our find-
ings.
Different studies have been performed on the relapse rate
of brucellosis after an appropriate course of treatment, by
socio-economic status and treatment regimen, and differing
results have been reported. For example in a Turkish study in
1999, the results of two different drug regimens, ciproflox-
acin—rifampin and doxycycline—rifampin (DR), were com-
pared in a group of 40 patients with brucellosis. In this study
the relapse rate in the DR group was 15% while it was 10% in
the other group.12 Also in a similar study in 1999 in Spain the
relapse rate was 12.5% with a netilmicin—doxycycline regi-
men.13 In another study of the DR regimen this rate was 16%,
but in a study in Turkey in 2002 the relapse rate with the DR
regimen was 6.7%.14 In our study the relapse rate in the DR
group was less than that reported in other studies15, and the
ADR group had a lower relapse rate than that of this standard
treatment, though this was not significant.
In another study in Iran two antibiotic regimens — co-
trimoxazole—doxycycline (CD) vs. co-trimoxazole—rifampin
(CR) — were compared over a period of two months. Failure
of treatment plus relapse was 15.7% in the CD group and
26.4% in the group taking the CR regimen.16
In patients with brucellosis, even after appropriate anti-
biotic therapy, a relapse rate of 10% has been reported in
the literature. This might be due to the intracellular posi-
tion of the organism, which protects them from the effects
of antibiotics and from the immune mechanisms of the
host.2,3
More patients were negative for the 2-ME test at two- and
six-months in the ADR group, which means that not only did
this test become negative in more patients undergoing the
ADR regimen, but this also happened in a shorter time.
Drug side-effects are another feature that may limit
treatment. Since in the ADR regimen three drugs were used,
and because aminoglycosides have multiple side-effects, we
expected a higher rate of side-effects compared to the DR
group, but the difference was not significant. In fact we did
not have any severe complications in either of the groups that
might have led to any discontinuation of the treatment. In
the short-term use of amikacin (seven days) we did not have
any aminoglycoside-specific side-effects such as nephrotoxi-
city or ototoxicity.
156 M. Ranjbar et al.Given the fact that the ADR regimen had higher efficacy
and more rapid action in terms of relief of symptoms com-
pared to the DR regimen, and that no significant difference in
drug side-effects and disease relapse existed in the patients
of either group, adding amikacin to the DR standard treat-
ment regimen seems beneficial.
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